3 ML insulin glargine-yfgn 100 UNT/ML Pen Injector
Managing this medication for someone you care for? Eleplan keeps diagnoses, medications and appointments in one plan.
Start free with EleplanClinical drug
3 ML insulin glargine-yfgn 100 UNT/ML Pen Injector
100 UNT/ML · Pen Injector · injection
A form of insulin glargine-yfgn →
3 ML insulin glargine-yfgn 100 UNT/ML Pen Injector — Insulins and analogues for injection, long-acting. Strength, form, class, interactions & more.
Active ingredient
Classification
Insulins and analogues for injection, long-actingInsulin Analog
Drug interactions
Insulin Glargine-yfgn has several clinically significant drug interactions that may affect blood glucose levels.
- majorantidiabetic agents — may increase the risk of hypoglycemia
- majorACE inhibitors — may increase the risk of hypoglycemia
- majorangiotensin II receptor blocking agents — may increase the risk of hypoglycemia
- majordisopyramide — may increase the risk of hypoglycemia
- majorfibrates — may increase the risk of hypoglycemia
- majorfluoxetine — may increase the risk of hypoglycemia
- majormonoamine oxidase inhibitors — may increase the risk of hypoglycemia
- majorpentoxifylline — may increase the risk of hypoglycemia
- majorpramlintide — may increase the risk of hypoglycemia
- majorsalicylates — may increase the risk of hypoglycemia
- majorsomatostatin analogs (e.g., octreotide) — may increase the risk of hypoglycemia
- majorsulfonamide antibiotics — may increase the risk of hypoglycemia
- majorGLP-1 receptor agonists — may increase the risk of hypoglycemia
- majorDPP-4 inhibitors — may increase the risk of hypoglycemia
- majorSGLT-2 inhibitors — may increase the risk of hypoglycemia
- majoratypical antipsychotics (e.g., olanzapine and clozapine) — may decrease the blood glucose lowering effect
- majorcorticosteroids — may decrease the blood glucose lowering effect
- majordanazol — may decrease the blood glucose lowering effect
- majordiuretics — may decrease the blood glucose lowering effect
- majorestrogens — may decrease the blood glucose lowering effect
- majorglucagon — may decrease the blood glucose lowering effect
- majorisoniazid — may decrease the blood glucose lowering effect
- majorniacin — may decrease the blood glucose lowering effect
- majororal contraceptives — may decrease the blood glucose lowering effect
- majorphenothiazines — may decrease the blood glucose lowering effect
- majorprogestogens (e.g., in oral contraceptives) — may decrease the blood glucose lowering effect
- majorprotease inhibitors — may decrease the blood glucose lowering effect
- majorsomatropin — may decrease the blood glucose lowering effect
- majorsympathomimetic agents (e.g., albuterol, epinephrine, terbutaline) — may decrease the blood glucose lowering effect
- majorthyroid hormones — may decrease the blood glucose lowering effect
- moderatealcohol — may increase or decrease the blood glucose lowering effect
- moderatebeta-blockers — may increase or decrease the blood glucose lowering effect and blunt signs and symptoms of hypoglycemia
- moderateclonidine — may increase or decrease the blood glucose lowering effect and blunt signs and symptoms of hypoglycemia
- moderatelithium salts — may increase or decrease the blood glucose lowering effect
- unknownpentamidine — may cause hypoglycemia followed by hyperglycemia
- unknownguanethidine — may blunt signs and symptoms of hypoglycemia
- unknownreserpine — may blunt signs and symptoms of hypoglycemia
Real-world adverse events (FAERS)
Hypoglycaemia1,577Blood Glucose Increased1,513Acute Kidney Injury969Dyspnoea957Nausea911Hyperglycaemia909Diarrhoea866Drug Ineffective866
Source: RxNorm + openFDA + RxClass + FAERS · 2026
Look up another medication